Hypertension is a complex condition often characterized by elevated sympathetic activity, which recent studies have linked to neuroinflammation mediated by microglia in the hypothalamic paraventricular nucleus (PVN). Wei et al. demonstrated that microglia respond early to hypertensive stimuli, suggesting a pivotal role in sympathetic excitation during hypertension (ref: Wei doi.org/10.1016/j.immuni.2024.07.011/). In a separate study, Xu et al. explored the relationship between subendocardial perfusion and myocardial injury in hypertensive patients, revealing that impaired perfusion correlates with adverse cardiac outcomes, including heart failure and myocardial infarction (ref: Xu doi.org/10.1161/CIRCULATIONAHA.123.067083/). Furthermore, the CAMEO-DAPA trial by Tada et al. highlighted the benefits of Dapagliflozin in enhancing arterial compliance during exercise in heart failure with preserved ejection fraction (HFpEF), indicating potential therapeutic avenues for managing hemodynamic congestion (ref: Tada doi.org/10.1161/CIRCULATIONAHA.124.068788/). Integrative studies have also identified asporin as a protective factor in pulmonary arterial hypertension, linking genetic factors to cardiovascular health (ref: Hong doi.org/10.1161/CIRCULATIONAHA.124.069864/). Overall, these findings underscore the multifaceted nature of hypertension and its cardiovascular implications, emphasizing the need for comprehensive management strategies.